Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
This article gives an overview of OIC, its current management and more specifically the development and approval of naloxegol, including pharmacokinetics, details of various clinical trials, adverse effects and its current status for the management of OIC.
Source: Journal of Pharmacology and Pharmacotherapeutics - Category: Drugs & Pharmacology Authors: Tejus AnantharamuSushil SharmaAjay Kumar GuptaNavdeep DahiyaDick B Singh BrashierAshok Kumar Sharma Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Pain | Clinical Trials | Constipation | Drugs & Pharmacology | Oral Cancer | Pain | Pain Management | Palliative | Palliative Care